Cerevel Therapeutics Holdings, Inc. logo

Cerevel Therapeutics Holdings, Inc.

NASDAQ:CERE

Overview | Financials
Company Name Cerevel Therapeutics Holdings, Inc.
Symbol CERE
Currency USD
Price 44.96
Market Cap 8,191,487,560
Dividend Yield 0%
52-week-range 19.59 - 44.99
Industry Biotechnology
Sector Healthcare
CEO Mr. Ronald C. Renaud Jr., M.B.A., MBA
Website https://www.cerevel.com

An error occurred while fetching data.

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial

Related Stocks

Amedisys, Inc. logo

Amedisys, Inc.

AMED

96.91 USD

Guardant Health, Inc. logo

Guardant Health, Inc.

GH

26.79 USD

iRhythm Technologies, Inc. logo

iRhythm Technologies, Inc.

IRTC

76.61 USD

Novavax, Inc. logo

Novavax, Inc.

NVAX

13.61 USD

Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc.

ARWR

21.49 USD

Surgery Partners, Inc. logo

Surgery Partners, Inc.

SGRY

31 USD

LivaNova PLC logo

LivaNova PLC

LIVN

48.53 USD

CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

CRSP

48.94 USD

QuidelOrtho Corporation logo

QuidelOrtho Corporation

QDEL

45.47 USD

Financials

Numbers are in millions USD

Numbers are in millions USD